Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475]
1 Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland; Neuro-Oncology, General and Stereotaxic Neurosurgery Service, University Hospital of Lille, Lille, France; University of Lille, Inserm, U-1192 Lille, France. Electronic address: emilie.lerhun@usz.ch.
2 European Organization for Research and Treatment of Cancer, Brussels, Belgium.
3 Institute of Neuropathology, Medical Faculty, Heinrich Heine University and University Hospital Düsseldorf, and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Düsseldorf, Germany.
4 The Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
5 Univ. Lille, UFR3S - Laboratoire d'Histologie, Lille, France.
6 CHU Lyon, Neuro-Oncology, Lyon, France.
7 Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
8 Department of Neurology - NeuroOncology and Wilhelm Sander Neuro-Oncology Unit, University Hospital Regensburg, Regensburg, Germany.
9 Neuro-oncology, CHU Timone, Marseille, France.
10 Division of Oncology, Department of Medicine 1, Medical University, Vienna, Austria.
11 Department of Biomedical imaging and Image-guided Therapy, Medical University of Vienna, Austria; Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, 3500 Krems, Austria.